Efficacy of Hepatoprotective Agents With or Without Antiviral Drugs on Liver Function and Fibrosis in Patients With Hepatitis B: A Meta-Analysis

Li-Hui Long 1,2; Cai-Qin Xue 1; Jun-Feng Shi 1; Juan-Ni Dong 1; Li Wang 2

1Department of Pharmacy, the First Affiliated Hospital of Xi’an Medical College, Xi’an, Shaanxi 710077, China
2Research Division, the First Affiliated Hospital of Xi’an Medical College, Xi’an, Shaanxi 710077, China
*Corresponding Author: Li-Hui Long, Department of Pharmacy, the First Affiliated Hospital of Xi’an Medical College, Xi’an, Shaanxi 710077, China. Tel: +86-2984277599, Fax: +86-2984277599, E-mail: llhbjd@126.com

Received: April 11, 2015; Revised: May 17, 2015; Accepted: May 31, 2015

Context: To systematically evaluate the effects of hepatoprotective agents, when delivered either alone or in combination with other antiviral or non-antiviral drugs in patients with hepatitis B and hepatic fibrosis.

Objectives: The current randomized controlled clinical trials aimed to evaluate the efficacy of combinations of antiviral and non-antiviral hepatoprotective agents on indexes of liver function and liver fibrosis in patients with hepatitis B.

Data Sources: Published literatures in Chinese and English on hepatoprotective treatment strategies for chronic hepatitis B and liver fibrosis were searched in three databases and randomized controlled clinical trials were selected.

Study Selection: Data were extracted according to a variety of inclusion and exclusion criteria. Meta-analysis was employed to analyze the data.

Results: A total of 22 randomized controlled trials encompassing 1,714 cases were considered in the meta-analysis. The obtained results indicated that the combination of antiviral drug and hepatoprotective agent was better than antiviral drug alone to improve liver function. Similarly, regarding liver fibrosis, using two different hepatoprotective agents was better than using one agent. The normalization rates of Aminotransferase (ALT) and total Bilirubin (TBil) were improved 25.7% by two hepatoprotective agents compared to the single agent. Acetylcysteine was superior to ursodeoxycholic acid or silibinin to reduce ALT. Ursodeoxycholic acid was superior to acetylcysteine or silibinin to reduce TBIL.

Conclusions: Hepatoprotective agents combined with antiviral drugs can significantly improve liver function and liver fibrosis parameters in patients with hepatitis B.

Keywords: Hepatitis B; Liver Cirrhosis; Meta-Analysis; Ursodeoxycholic Acid (UDCA); Silibinin; Acetylcysteine

1. Context

At present, Hepatitis B Virus (HBV) infection is an important public health problem worldwide. Hepatitis B can lead to serious liver diseases, including cirrhosis, liver cancer. In China, approximately 120 million people are infected with the Hepatitis B Virus (1). Alavian et al. reported that about 1 million people are infected with HBV in Iran, and 15% to 40% of the patients with hepatitis B may develop cirrhosis or liver cancer (2). Liver fibrosis is a healing response, but the excessive accumulation of extracellular matrix (ECM) components in the liver often leads to severe forms of liver fibrosis, and ultimately cirrhosis with liver dysfunction (3-5). Early cirrhosis may be reversible. Therefore, prompt diagnosis and intervention are critical in limiting disease progression (6). Clinically, the existing hepatoprotective agents include Ursodeoxycholic acid (UDCA), silibinin, and N-acetylcysteine (NAC).

UDCA is a hydrophilic bile acid, which alters the ratio of hydrophilic-to-hydrophobic components in the bile acid pool. It promotes the secretion of endogenous bile acids such as chenodeoxycholic and lithocholic acid, and improves cholestasis. UDCA is mainly used to treat primary biliary cirrhosis, hepatitis B associated liver fibrosis, and cholestatic liver disease, the efficacy is certain. Some studies reported that UDCA protects liver cell membrane and enhances immune function. These mechanisms may be related to the ability of ursodeoxycholic acid to regulate cell cycle, apoptosis and protein biosynthesis of liver cells. Alternatively, the increased pool of hydrophilic bile acid and the stability of the cell membrane may play an important protective role (7, 8). UDCA, which causes minimal damage and is non-toxic to liver cells, is an effective hepatoprotective agent and cholagogue (9). Results of long-term observational studies showed that ursodeoxycholic acid can significantly reduce the development of hepatic fibrosis (8, 10, 11).

Silibinin is derived from milk thistle, an important medicinal plant that is roots, leaves and seeds exert a variety of therapeutic effects, including hepatoprotective, antioxidant, and anti-lipogenic properties (12). In the United States and Europe, about 65% of patients with liver dis-
ease use Chinese medical preparations which include milk thistle as their most common ingredient (13). Silymarin, a mixture of flavonoids and wood ester pigment compounds, is extracted from milk thistle seeds. Silymarin contains silibinin, silychristin, and silymarin Ning with a large amount of silibinin. It is noteworthy that, silibinin is the main active ingredient of silymarin (14). In recent years, silibinin has been used to treat liver cirrhosis, hepatitis, liver fibrosis and alcoholic liver disease (15).

N-acetylcysteine (NAC) is an intracellular glutathione precursor, which can enhance the activity of glutathione transferase and promote the detoxification of free radicals. Nitric oxide (NO) and its metabolite can improve microcirculation, increase tissue oxygen, and enhance the repair of damaged tissue (16, 17). In recent years, clinical studies have demonstrated that NAC is not only effective to treat liver failure caused by excessive acetaminophen (paracetamol), but is also useful for liver disease arising from other causes (18). NAC reduces serum Total Bilirubin (TBil) and aminotransferases, and increases Prothrombin activity (PTA) in patients with severe chronic hepatitis B (19).

2. Objectives

The current study aimed to search randomized controlled clinical trials to evaluate the efficacy of antiviral and non-antiviral hepatoprotective agents combinations on the indexes of liver function and liver fibrosis in patients with hepatitis B.

3. Data Sources

Papers written in either English or Chinese describing the use of hepatoprotective agents to treat hepatitis and liver fibrosis were retrieved. Using “chronic hepatitis B, hepatitis B, HBV, liver fibrosis, hepatoprotective, silibinin (silymarin, silybin meglumine), acetylcysteine and ursodeoxycholic bile acid (UDCA)”, the study retrieved papers indexed in the China national knowledge internet (CNKI) (2000 - 2012), Pubmed (1983-2013), Embase (2000 - 2013) and Cochrane databases (1992 - 2012).

4. Study Selection

4.1. Inclusion and Exclusion Criteria

4.1.1. Inclusion Criteria

Hepatitis B infection or liver fibrosis; chronic hepatitis B was diagnosed if HBV history or HBV markers were persistently positive for more than six months and serum alanine aminotransferase levels exceeded 80 IU/L, and hepatic fibrosis was estimated by indexes containing the following markers: HA, LN, C-IV, PIIIP (13). Results indicators including Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), TBIL, gamma-Glutamyl Transpeptidase (γ-GGT), Alkaline Phosphatase (ALP), Hyaluron-ic acid (HA), Laminin (LN), Collagen type IV (CIV), and Procollagen III peptide (PIIIP). Trials were limited to those comparing the efficacy of different drugs or placebo.

4.1.2. Exclusion Criteria

Studies in which non-protective liver drugs were used to treat viral hepatitis or liver fibrosis; animal experiments and reviewed papers that did not contain clinical data; pregnant and lactating female patients with liver disease. The therapy course was less than three weeks; liver biochemical markers were normal.

4.2. Outcome Indicators

Outcomes were reported in terms of efficacy as follows: 1) Markedly effective: patients underwent full recovery or exhibited significant improvements in their clinical symptoms; levels of ALT, AST, GGT, TBIL and other basic indicators of liver function were restored to within the normal range. 2) Effective: moderate improvement of clinical symptoms, signs and liver function. 3) Ineffective: no obvious improvement or exacerbation of symptoms, signs and liver function indexes.

4.3. Statistical Analysis

RevMan5.2 software was used to analyze the data. For classified data, risk ratio (RR) and 95% confidence interval (95% CI) were used. For continuous data, weighted mean difference (WMD) and 95% CI were used. If I2 < 50%, the test was considered uniform with no statistically significant heterogeneity, the fixed effects model was used if I2 > 50%, a random effects model was used. A Funnel plot was used to evaluate possible publication bias.

5. Data Extraction

Two authors discussed all data sets before extracting them from the published literature. To avoid subjective bias, names of the authors, publications, year, and country were omitted during the data extraction process. Retrieved data included: (1) liver biochemical indicators: ALT (U/L), GGT (U/L), ALP (U/L) and TBIL (U/L); (2) liver fibrosis markers: HA (μg/L), LN (μg/L), IV-C (μg/L) and PIIIP (μg/L). Disagreements were resolved by discussion and consensus.

6. Results

6.1. Retrieval Results

Initially, 245 papers were retrieved by screening the title, abstract, and inclusion and exclusion criteria. Finally, 22 standard randomized controlled trials were included, with a total of 1,756 subjects, among whom 893 subjects were in the treated group, and 821 subjects were in the control group (Table 1).
### Table 1. Basic Characteristics of the Included Studies

| Included Studies | Cases | Intervening Measures | Course of Treatment | Efficacy of Indicators |
|------------------|-------|----------------------|---------------------|------------------------|
| **Experimental Group** | **Control Group** | **Experimental Group** | **Control Group** |                       |
| Xia et al. (20) | 58 | NAC (8 g/d) + basic treatment | Basic treatment (Potassium magnesium aspartate 2 g/d + promote the liver cell auxin 0.1 g/d + plasma 200 ml qod + other symptomatic and supportive treatments) | 30 d | TBIL |
| Shi et al. (21) | 20 | NAC (8 g/d) + basic treatment | Basic treatment (Vitamin K 10 mg/d + promote the liver cell auxin 20 mg/d + plasma 200 ml qod or albumin 10 g qod + ranitidine 150 mg po tid + other symptomatic and supportive treatments) | 45 d | ALT, AST, TBIL |
| Wang et al. (19) | 50 | NAC (8 g/d) + GSH (1.2 g/d) | GSH (1.2 g/d) | 28 d | ALT, AST, TBIL |
| Shohrati et al. (22) | 18 | NAC (1.2 g/d) + basic treatment | Basic treatment (lamivudine + pegylated interferon + adefovir) | 45 d | ALT, AST, ALP, TBIL |
| Wu et al. (23) | 72 | NAC (8 g/d) + basic treatment | Basic treatment (Vitamin K 10 mg/d + promote the liver cell auxin 20 mg/d + plasma 200 ml qod or albumin 10 g qod + ranitidine 150 mg po tid + other symptomatic and supportive treatments) | 45 d | ALT, AST, TBIL |
| Wang et al. (24) | 42 | UDCA (0.5 g/d) + GSH (1.2 g/d) | Yinzhihuang (30 ml/d) | 8 w | ALT, GGT, ALP, TBIL |
| Fabris et al. (25) | 40 | UDCA (0.6 g/d) + lactulose (100-200 g/d) | Lactulose (100-200 g/d) | 3 w | ALT, AST, GGT, ALP, TBIL |
| Angulo et al. (26) | 21 | UDCA (13-15 mg/kg/d) | D-penicillamine (the dosage was unclear) | 24 w | AST, TBIL |
| Cao et al. (27) | 53 | UDCA (0.75 g/d) + Ade-methionine (1.0 g/d) | Ruhuang injection (60 ml/d) | 4 w | ALT, GGT, ALP, TBIL |
| Qureshi et al. (28) | 18 | UDCA (0.5 g/d) | Placebo (unclear) | 12 w | ALT |
| Ratziu et al. (29) | 62 | UDCA (0.5 g/d) | Placebo (unclear) | 48 w | ALT, AST, GGT, TBIL |
| Tkacz et al. (12) | 45 | Silibinin (0.42 g/d) | Placebo (unclear) | 45 d | ALT, AST, TBIL |
| Flisiak et al. (30) | 15 | Misoprostol (0.8 g/d) | Silibinin (0.21 g/d) | 12 w | ALT, TBIL |
| Flisiak et al. (31) | 25 | Silibinin (0.21 g/d) + misoprostol (0.8 g/d) | Placebo (unclear) | 24 w | ALT, AST, GGT, TBIL |
| Gu et al. (32) | 33 | Silibinin (0.6 g/d) + oxymatrine (0.6 g/d) | Silibinin (0.6 g/d) | 12 w | ALT, TBIL |
| Bao et al. (33) | 42 | Silibinin (0.36 g/d) + Interferon α-16 (300 million U, q.o.d.) | Interferon α-16 (300 million U, qod.) | 12 w | ALT, AST |
| Bao et al. (34) | 86 | Silibinin (0.36 g/d) + Lamivudine (0.1 g/d) | Lamivudine (0.1 g/d) | 48 w | ALT, AST, ALP, TBIL |
Long L et al.

Hepat Mon. 2015;15(7):e29052

| Study          | Subjects | Patients | Treatment Details                                                                 | Control | Treatment | Number of Weeks | Control Group | Treatment Group | Number of Weeks |
|----------------|----------|----------|-----------------------------------------------------------------------------------|---------|-----------|-----------------|---------------|-----------------|-----------------|
| Kim et al. (35)| 42       | 43       | UDCA (0.6 g/d) + Candesartan (0.008 g/d)                                          | HA, LN, IV-C, PIIIP | Candesartan (0.008 g/d) | 24 w            | ALT, AST, GGT, TBIL | NA              | HA, PC, CIV, LN  |
| Wang et al. (36)| 45     | 44       | Silibinin (0.315 g/d) + protect liver treatment + Lamivudine (0.1 g/d)           | NA      | Protect liver treatment (energy mixture, inosine, salvia miltiorrhiza, promoting liver cell growth hormone and vitamin) + Lamivudine (0.1 g/d) | 42 w            | HA, PC, CIV, LN  | NA              | HA, PC, CIV, LN  |
| Wu et al. (37) | 40      | 40       | UDCA (13-15 mg/kg/d) + Fuzhenghuayu Capsules (4.5 g/d)                            | NA      | Fuzhenghuayu (4.5 g/d)               | 48 w            | ALT, AST, GGT, TBIL, ALP, HA, LN, IVC, PHIP | NA              | HA, PC, CIV, LN  |
| Mao et al. (38) | 36     | 34       | Tanshinone (0.06 g/d) + Oxymatrine (0.6 g/d)                                     | NA      | Tanshinone (0.06 g/d)                | 4 w             | ALT, AST, TBIL, HA, LN, PHIP, IVC | NA              | HA, PC, CIV, LN  |
| Zhou et al. (39)| 30     | 30       | Valsartan (0.08 g/d) + Silibinin (0.14 g/d)                                      | NA      | Silibinin (0.14 g/d)                 | 12 w            | HA, LN, IV-C, PHIP | NA              | HA, PC, CIV, LN  |

6.2. Treatment Type

The meta-analysis groups were: 1) liver protective drug plus antiviral drug versus antiviral drug alone to assess efficacy of altering ALT, AST, ALP and TBIL levels (Table 1; Figure 1); 2) liver protective drug (treatment group) versus placebo to assess protective effects in terms of ALT and TBIL (Table 1; figures 3 and 4); 3) combination of two hepatoprotective agents versus a single agent in terms of ALT, AST, ALP, GGT, TBIL (Table 1; Figure 4); 4) one protective agent versus another in terms of normalization rates of ALT and TBIL (Table 1; Figure 5); 5) evaluation of the effects of a combination of two kinds of protective agents versus a single protective agent in terms of HA, LN, IV-C and PHIP (Table 1; figures 6 and 7) as hepatic fibrosis markers.

6.3. Hepatoprotective Drug Combined With Antiviral Drug Alone

Six randomized controlled trials reported on the use of a hepatoprotective drug in combination with an antiviral agent treatment of chronic hepatitis B. The test and control groups included 741 and 645 subjects, respectively. There was a statistically significant heterogeneity between the studies (I2 > 50%), and hence, a random-effects model was used. Meta-analysis showed that using a combination of hepatoprotective and antiviral drugs was more effective than a single antiviral agent to reduce serum levels of ALT, AST, ALP and TBIL. ALT (WMD = -22.98; 95% CI [-34.98, -10.97]), AST (WMD = -26.20; 95% CI [-44.60, -7.81]), ALP (WMD = -56.19; 95% CI [-85.27, -27.11]) and TBIL (WMD = -5.58; 95% CI [-9.50, 1.66]) (Figure 1).

6.4. Hepatoprotective Agents vs. Placebo

Five randomized controlled clinical trials reported the effects of three hepatoprotective agents compared with placebo on liver function indexes in patients with chronic hepatitis B, including ALT and TBIL. In these trials, the control and treatment groups included 144 and 140 subjects, respectively; since there was no significant heterogeneity between the studies (I2 < 50%), a fixed-effect model was applied. Meta-analysis showed that all three hepatoprotective agents significantly decreased ALT levels in patients with hepatitis B. NAC was associated with greater efficacy compared to UDCA and silibinin. The impact of UDCA and silibinin on ALT levels in patients with hepatitis B were considerable: NAC (WMD = -25.66; P = 0.0002, 95% CI [-39.02, -12.31]), UDCA (WMD = -22.32; P = 0.03, 95% CI [-42.28, -23.36]), silibinin (WMD = -22.40; P = 0.11, 95% CI [-49.52, 4.72]) (Figure 2).

UDCA was superior over NAC and silibinin to reduce TBIL in patients with hepatitis B. Meta-analysis showed that NAC (WMD = -2.56; P = 95% CI [-4.95, -0.17]), UDCA (WMD = -3.48; 95% CI [-7.37, -0.31]), and silibinin (WMD = -2.09; 95% CI [-8.70, 4.52]). However, the differences were not statistically significant (I2 = 0%) using a fixed-effects model (Figure 3).

6.5. Two Kinds of Hepatoprotective Agents vs. a Single Hepatoprotective Agent

Five randomized controlled clinical trials were employed to test the efficacy of two hepatoprotective agents compared to only one to treat patients with chronic hepatitis B. There were 618 subjects in the two hepatoprotective agents, and the single hepatoprotective agent groups, respectively. The heterogeneity between the studies was statistically significant (I2 > 50%). Using a random-effects model, meta-analysis showed that the two hepatoprotective agents group was better than the single agent to reduce ALT, AST, GGT, ALP and TBIL levels in patients with hepatitis B. ALT (WMD = -31.44; 95% CI [-48.57, 44.32]), AST (WMD = -14.54; 95% CI [-29.24, 0.16]), GGT (WMD = -26.98; 95% CI [-54.66, 0.70]), ALP (WMD = -29.86; 95% CI [-52.65, -2.09]), and TBIL (WMD = -4.84; 95% CI [-9.86, 0.18]) (Figure 4).

---

a Abbreviations: ALT, Alanine aminotransferase Aminotransferase; ALP; alkaline Alkaline phosphatase; AST, aspartate Aminotransferase; CIV collagen Collagen type IV; HA, hyaluronic Hyaluronic acid Acid; LN, laminin Laminin; PIIIP, procollagen Procollagen III peptide Peptide; TBIL, total bilirubin; γ-GGT, gamma-glutamyl Glutamyl transpeptidase Transpeptidase
In patients with chronic hepatitis B infection treated with combination hepatoprotective and antiviral drug vs. antiviral drug alone. Data are presented as pooled mean difference using a random-effects model and 95% confidence intervals.
6.6. Effects of two Versus one Hepatoprotective Agent on Recovery of Liver Function in Patients With Hepatitis B

Three randomized controlled clinical trials reported the effects of combining two hepatoprotective drugs compared to a single agent on the recovery rate of liver indicators in patients with hepatitis B; 173 subjects who used a combination of two agents were compared to 123 subjects who used only one agent. The heterogeneity between the studies was statistically significant ($I^2 = 0\%$, $P = 0.98$). Therefore, a fixed-effects model was used. Compared with the single agent group, meta-analysis showed that using a combination of two hepatoprotective drugs was more effective than only one in restoring liver indicators to normal levels (two hepatoprotective agents group vs. single hepatoprotective agent group = 75.2% vs. 49.5%). ALT (72.3% vs. 48.7%, RR = 1.44, 95% CI [1.01, 2.04]), TBIL (77.8% vs. 50%, RR = 1.53, 95% CI [1.21, 1.95]). The recovery rate of the group that used two hepatoprotective agents was 25.7% higher than the one treated by a single agent, (RR = 1.50, $P < 0.0001$, 95% CI [1.23, 1.83]) (Figure 5).
6.7. Effects of Hepatoprotective Agents on Liver Fibrosis Indexes in Patients With Hepatitis B

Three randomized controlled clinical trials reported the effects of hepatoprotective agents on liver fibrosis markers, HA, IV-C and PIIIP. From the three studies, the test and control groups consisted of 121 and 118 subjects, respectively. The heterogeneity between the studies was statistically significant ($I^2 > 50\%$). Thus, a random-effects model was used. The results indicated that hepatoprotective agents were indeed associated with improved indices of hepatic fibrosis compared to placebo: HA (WMD = -55.65, 95% CI [-75.00, -36.31]), IV-C (WMD = -29.23, 95% CI [-41.21, -17.25]), PIIIP (WMD = -53.79, 95% CI [-69.03, -38.55]) (Figure 6).

Four randomized controlled clinical trials reported the effects of combined hepatoprotective agents versus a single agent on the liver fibrosis index, LN. The group
In patients with chronic hepatitis B infection treated with the combination of two liver protective drugs vs. one liver protective drug. Data are presented as pooled mean difference using a random-effect model, and 95% confidence intervals.
representing the combined hepatoprotective agents included 151 subjects, whereas the single hepatoprotective agent group had 148 subjects. There was no significant heterogeneity (I² < 50%); therefore, a fixed-effects model was used. Meta-analysis showed that the two hepatoprotective agents was superior to the single one in terms of reducing LN levels (WMD = -33.91, 95% CI [-40.51, -27.31]) (Figure 7).

6.8. Assessment of Publication Bias
A Funnel plot analysis of bias among 12 trials on the effects of hepatoprotective agents on normalization of ALT, AST and TBIL was conducted, in patients with hepatitis B (Figure 8). The Funnel plot showed that the distribution of the samples were asymmetrical, suggesting that some of the test methodologies may have been of low quality, and publication bias may have been present.

Figure 5. Meta-Analysis Forest Plots Indicating the Normalization Rates of ALT and TBIL

| Study or Subgroup | Experimental | Control | Odds Ratio M-H, Fixed, 95% CI |
|-------------------|-------------|---------|-----------------------------|
| Events | Total | Events | Total | Weight | M-H, Fixed, 95% CI |
| 5.1.1 The normalization rate of ALT | | | | | |
| Wang N et al. 2008 | 38 | 50 | 13 | 24.0% | 2.92 [1.06, 8.09] |
| Yang XY 1999 | 9 | 15 | 7 | 16 | 15.6% | 1.93 [0.46, 8.05] |
| Subtotal (95% CI) | 65 | 41 | 39.6% | 2.53 [1.10, 5.80] |
| Total events | 47 | 20 | | | |
| Heterogeneity: Ch² = 0.22, df = 1 (P = 0.64); I² = 0% | | | |
| Test for overall effect: Z = 2.19 (P = 0.03) | | | |
| 5.1.2 The normalization rate of TBIL | | | | | |
| Wang N et al. 2008 | 45 | 58 | 28 | 36.5% | 3.89 [1.60, 8.03] |
| Xia G et al. 2009 | 38 | 60 | 13 | 24.0% | 2.92 [1.06, 8.09] |
| Subtotal (95% CI) | 108 | 82 | 60.4% | 3.32 [1.77, 6.25] |
| Total events | 83 | 41 | | | |
| Heterogeneity: Ch² = 0.09, df = 1 (P = 0.76); I² = 0% | | | |
| Test for overall effect: Z = 3.73 (P = 0.0002) | | | |
| Total (95% CI) | 173 | 123 | 100.0% | 3.01 [1.82, 4.97] |
| Total events | 130 | 61 | | | |
| Heterogeneity: Ch² = 0.56, df = 3 (P = 0.91); I² = 0% | | | |
| Test for overall effect: Z = 4.31 (P < 0.0001) | | | |
| Test for subgroup differences: Ch² = 0.26, df = 1 (P = 0.61); I² = 0% | | | |

In patients with chronic hepatitis B infection treated with two vs. one hepatoprotective agent. Data are presented as pooled relative risks, adopted fixed-effect model and 95% confidence intervals, by trial.
**Figure 6.** Meta-Analysis With Forest Plots Effects of two Hepatoprotective Agents vs. a Single Hepatoprotective Agent on Levels of HA, IV-C and PIIIP in patients with liver fibrosis. Data are presented as pooled mean difference using a random-effects model and 95% confidence intervals, by trials.

| Study or Subgroup | Experimental Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference | IV, Random, 95% Cl | Mean Difference |
|-------------------|------------------|----|-------|------|----|-------|--------|----------------|------------------|----------------|
| 6.1.1 The reduce amounts of HA | | | | | | | | | | |
| Mao ZY et al. 2014 | 88.2 | 37.5 | 36 | 139.1 | 46.5 | 34 | 10.4% | -50.90 [70.76, -31.04] | | |
| Wu Y et al. 2012 | 106.5 | 20.2 | 40 | 187.2 | 21.1 | 40 | 13.0% | -69.70 [78.75, -60.65] | | |
| Zhang XX et al. 2012 | 179.95 | 52.62 | 45 | 216.02 | 74.03 | 44 | 8.6% | -37.37 [64.11, -10.63] | | |
| Subtotal (95% Cl) | 121 | 118 | | | | | | 32.0% | -55.65 [75.00, -36.31] | |
| Heterogeneity: Tau² = 203.90; Chi² = 7.01, df = 2 (P = 0.03); P = 71% |
| Test for overall effect: Z = 5.64 (P < 0.00001) |

| Study or Subgroup | Experimental Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference | IV, Random, 95% Cl | Mean Difference |
|-------------------|------------------|----|-------|------|----|-------|--------|----------------|------------------|----------------|
| 6.1.2 The reduce amounts of IV-C | | | | | | | | | | |
| Mao ZY et al. 2014 | 45.6 | 26.3 | 36 | 69.3 | 37.2 | 34 | 11.6% | -23.70 [38.87, -8.53] | | |
| Wu Y et al. 2012 | 132.8 | 16.5 | 40 | 171.2 | 22.6 | 40 | 13.1% | -38.40 [47.07, 29.73] | | |
| Zhang XX et al. 2012 | 140.45 | 35.98 | 45 | 169.45 | 40.36 | 44 | 11.4% | -21.00 [36.90, -5.10] | | |
| Subtotal (95% Cl) | 121 | 118 | | | | | | 36.2% | -29.23 [41.21, -17.25] | |
| Heterogeneity: Tau² = 67.78; Chi² = 5.08, df = 2 (P = 0.00); P = 61% |
| Test for overall effect: Z = 4.78 (P < 0.00001) |

| Study or Subgroup | Experimental Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference | IV, Random, 95% Cl | Mean Difference |
|-------------------|------------------|----|-------|------|----|-------|--------|----------------|------------------|----------------|
| 6.1.3 The reduce amounts of PIIIP | | | | | | | | | | |
| Mao ZY et al. 2014 | 78.2 | 40.6 | 36 | 128.9 | 55.3 | 34 | 9.5% | -50.70 [74.12, -27.28] | | |
| Wu Y et al. 2012 | 122.1 | 16 | 40 | 105 | 22.6 | 40 | 13.1% | -62.90 [71.48, -54.32] | | |
| Zhang XX et al. 2012 | 170.8 | 49.52 | 45 | 208.37 | 66 | 44 | 9.2% | -37.57 [61.85, -13.29] | | |
| Subtotal (95% Cl) | 121 | 118 | | | | | | 31.8% | -53.79 [69.03, -38.55] | |
| Heterogeneity: Tau² = 99.17; Chi² = 4.27, df = 2 (P = 0.04); P = 63% |
| Test for overall effect: Z = 6.92 (P < 0.00001) |

Total (95% Cl): 363

Data are presented as pooled mean difference using a random-effects model and 95% confidence intervals, by trials.

**Figure 7.** Meta-Analysis Forest Plots of LN Levels in Patients With Liver Fibrosis Infection Treated with Two vs. one Hepatoprotective Agents

| Study or Subgroup | Experimental Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference | IV, Fixed, 95% Cl | Mean Difference |
|-------------------|------------------|----|-------|------|----|-------|--------|----------------|------------------|----------------|
| Mao ZY et al. 2014 | 66.8 | 37.4 | 36 | 91.4 | 51.2 | 34 | 11.7% | -24.60 [45.71, -3.49] | | |
| Wu Y et al. 2012 | 126 | 16.3 | 40 | 163.5 | 21.2 | 40 | 75.8% | -35.50 [43.79, -27.21] | | |
| Zhang XX et al. 2012 | 171.87 | 39.25 | 45 | 190.73 | 56.14 | 44 | 12.8% | -26.88 [47.03, -6.69] | | |
| Total (95% Cl) | 121 | 118 | | | | | | 100.0% | -33.13 [40.33, -25.92] | |
| Heterogeneity: Chi² = 1.31, df = 2 (P = 0.52); P = 9% |
| Test for overall effect: Z = 9.01 (P < 0.00001) |

Data are presented as pooled mean difference using a random-effects model, and 95% confidence intervals.
In conclusion, hepatoprotective drugs can effectively improve serum liver markers in patients with liver fibrosis when combined with antiviral or other hepatoprotective agents.

Acknowledgements

The current work was supported by the social development research project of Shaanxi science and technology agency (No. 2012K14-04-01) and the project of Xi’an medical college (No. XYFYI1-02).

Authors’ Contributions

Authors had equal contribution.

Funding/Support

The current research was financially supported by Shaanxi Science and Technology Agency (No. 2012K14-04-01); the project of Xi’an Medical College affiliated hospital (No. XYFYI1-02).

References

1. Liang GN, Chen LH. Glycyrrhizins injection combined with Danshen injection observe the effect of hepatitis B liver fibrosis. J Tibet Med. 2010;31(1):24-5.
2. Alavian SM, Tabatabaei SV, Ghadimi T, Beerdapour F, Kafi-Abad SA, Gharehbaghian A, et al. Seroprevalence of Hepatitis B Virus Infection and Its Risk Factors in the West of Iran: A Population-based Study. Int J Prev Med. 2012;3(1):770-5.
3. Bataller R, Brenner DA. Liver Fibrosis. J Clin Invest. 2005;115(2):209-18.
4. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655-69.
5. Kim BK, Kim do Y, Park JY, Ahn SH, Chon CY, Kim JK, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30(4):546-51.
6. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008;12(4):733-46.
7. Cao R, Hu XD, Cheng H. Observation on the clinical efficiency of adenosine combine with ursodeoxycholic acid in the treatment of chronic hepatitis B with severe jaundice. Chin Hosp Pharm J Dis. 2003;22(8):481-8.
8. Gao Y, Song MZ, Liang CR. Clinical Observation of Ademetio-nine Combined With Ursodeoxycholic Acid in the Treatment of Chronic Severe Cholestatic Hepatitis. Chin Hosp Pharm J Dis. 2013;14(1):68-9.
9. Joo SS, Kang HC, Won TJ, Lee DI. Ursodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1beta and nitric oxide in rat microglia. Arch Pharm Res. 2003;26(12):1067-73.
10. Fekaj E, Gjata A, Makhuni M. The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study. BMC Surg. 2013;13:38.
11. Boberg KM, Wisshoff T, Kjøllesdal KS, Stovring H, Kristiansen IS. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther. 2013;38(7):794-803.
12. Tkacz B, Dworniak D. [Sylimarol in the treatment of acute viral hepatitis]. Wiad Lek. 1985;38(8):631-6.
13. Wei F, Liu SK, Liu XY, Li ZJ, Li B, Zhou YL, et al. Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis. 2013;32(5):567-69.
14. Ren BR, Zhao YY, Xu BH, Wu JL, Chen J, Liang CY. Research of silymarin extraction and silibinin purification. Lishizhen Med Mater Med Res. 2012;23(1):655-6.
15. Feher J, Lengyel G. [Silymarin in the treatment of chronic liver diseases: past and future.]. Ovo Hettil. 2008;149(5):2413-8.

16. Hoffe E, Baum Y, Tabak A, Tateitman U. N Acetylcysteine increases the glutathione content and protects rat alveolar type II cells against paraquat-induced cytotoxicity. Toxicol Letters. 1996;84(1):7-22.

17. Harrison P, Wendon J, Williams R. Evidence of increased guanylate cyclase activation by acetylcysteine in fulminant hepatic failure. Hepatology. 1996;23(5):1067-72.

18. McClain CJ, Price S, Barve S, Devalarja R, Shedlofsky S. Acetaminophen hepatotoxicity: An update. Curr Gastroenterol Rep. 1999;4(1):42-9.

19. Wang N, Shi XF, Guo SH, Zhang DZ, Ren H. [A clinical study of N-acetylcysteine treatment in chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi. 2000;36(7):487-9.

20. Xia G. The clinical efficacy observation of acetylcysteine injection on 58 cases of chronic severe hepatitis B. West Chin Med J. 2009;24(5):1239-40.

21. Shi XF, Guo SH, Wu G, Wang ZY, Ren H, Liu Q. The clinical curative effect observation of acetylcysteine injection on 40 cases of chronic hepatitis B. J Chongqing Med Univ. 2005;30(1):145-21.

22. Shoohati M, Dermanaki F, Babaei F, Alavian SM. Evaluation of the effects of oral N-acetylcysteine and a placebo in paracinal and oxidative stress parameters of patients with chronic hepatitis B. Hepat Mon. 2010;10(2):95-100.

23. Wu G, Guo SH. The Clinic Study of N-Acetylcysteine Injection Therapy to Chronic Hepatitis B. Chongqing Med Univ. 2004;33(2):45-49.

24. Wang X, Shen S, Li N, Li Y. Effects of oral N-acetylcysteine and a placebo in paracinal and oxidative stress parameters of patients with chronic hepatitis B. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2003;28(2):171-5.

25. Fabris P, Iositti G, Mazzella G, Zanetti AR, Nicolini R, Pellizzer G, et al. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study. Aliment Pharmacol Ther. 1999;13(3):187-93.

26. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology. 1999;29(5):644-7.

27. CAO R, Hu XD, CHENG H, HUANG S, BAI T, GAN H, et al. Observation on the clinical efficiency of adenosine methionine combined with ursodeoxycholic acid in the treatment of chronic hepatitis B with severe jaundice. Chinese J Hos Pharm. 2013;6:019.

28. Qureshi H, Mehdi I, Ahmed WI, Alam SE. Role of ursodeoxycholic acid in lowering ALT in chronic liver disease. J Pak Med Assoc. 2006;56(3):130-1.

29. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, et al. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54(5):1001-9.

30. Flisiak R, Prokopowicz D. Effect of misoprostol on serum beta2-microglobulin in the course of viral hepatitis B. Eur J Gastroenterol Hepatol. 1999;11(8):1227-30.

31. Flisiak R, Prokopowicz D. Effect of misoprostol on the course of viral hepatitis B. Hepatogastroenterology. 1997;44(77):1419-25.

32. Gu XB, Yang XJ, Hua Z, Lu ZH, Zhang B, Zhu YF, et al. Effect of oxymatrine on specific cytotoxic T lymphocyte surface programmed death receptor-1 expression in patients with chronic hepatitis B. Chin Med J (Engl). 2012;125(8):1454-8.

33. Bao FY, Xie J. Silybin phospholipid complex combined with interferon treating hepatitis B. J Cent Plains Med. 2006;33(15):79-1.

34. Bao FY, Qiu PX. Analyzing the addictive therapy of silybin phospholipid complex treat chronic hepatitis B in 86 cases. Shanghai Med. 2006;26:26-31.

35. Kim MY, Cho MY, Baik SK, Jeong PH, Suk KT, Jang YO, et al. Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - a randomized open-label controlled study. Liver Int. 2012;32(6):977-87.

36. Wang H, Zhao YI, Xu KC. [Clinical and pathological study on effects of Qiangcan Capsule combined lamivudine on hepatic fibrosis in patients with chronic hepatitis B]. Zhongguo Zhe Ji He Za Zhi. 2006;26(1):978-80.

37. Wu Y, Yao DK, Zhu L. [Clinical observation on the safety and efficacy of ursodeoxycholic acid and fuzheng huayu capsule in the treatment of primary biliary cirrhosis]. Zhongguo Zhe Ji He Za Zhi. 2012;32(10):1477-82.

38. Mao ZY, Xiao M, Wu XJ, Yao TG. N-Acetylcysteine therapy on liver function in patients with chronic hepatitis B and liver fibrosis. Pract Clin Med. 2014;15(2):21-3.

39. Zhou XY, Gao C, Gao XC, Liu XJ, Li LH, Wang X. Clinical effects of valsartan on liver fibrosis indexes in patients with alcoholic liver cirrhosis. Chin J Integ Trad Western Med Liver Dis. 2014;24(2):85-6.

40. Gou W, Wang YL. To observe the effect of interferon α-2b combined with silymarin to treat chronic hepatitis B. Clin Hepatol. 2004;5:302.